Kidney Cancer Conference Highlights from ASCO GU 2025 - Takeaways - MDSpire
Advertisement
Kidney Cancer Conference Highlights from ASCO GU 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates, focused on clear cell renal cell carcinoma (ccRCC), you need to know from GU ASCO 2025.
COSMIC313 demonstrated that triplet therapy improves progression-free survival (PFS) but shows no overall survival (OS) benefit in first-line clear cell renal cell carcinoma (ccRCC).
2
KEYMAKER-U03 is investigating novel immune and targeted therapies for refractory ccRCC, aiming to enhance treatment options for difficult cases.
3
KIM1 has emerged as a promising prognostic and predictive biomarker for immunotherapy benefit in ccRCC, potentially guiding treatment decisions.
4
Checkmate 9 study indicated that Cabonivo shows significant PFS and OS benefits in intermediate and poor-risk patients, but not in favorable-risk patients.
5
Triplet therapy in Cosmic 313 was associated with higher rates of grade 3-4 adverse events, raising concerns about its safety and impact on treatment intensity.
